If you have commercial insurance
If your insurance does not cover Bonjesta®
or you do not have insurance:
Ask your doctor to prescribe through
Bonjesta at Home® and receive:
Questions? Call (844) 716-HOME (4663)
3 Easy Ways for Healthcare Professionals to Prescribe through the Bonjesta at Home® program:
Available only through: PhilRx, 150 E Campus View Blvd, Ste 210 Columbus, OH 43235
If you have commercial insurance
Questions? Call (347) 657-9766
Apollo Care Processing Information:
If your insurance does not cover Bonjesta®
or you do not have insurance:
Pay as
little as
GoodRx Processing Information:
BONJESTA® is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
BONJESTA® has not been studied in women with hyperemesis gravidarum.
BONJESTA® is contraindicated in women with any of the following conditions:
The most common adverse reaction (≥5 percent and exceeding the rate in placebo) is somnolence.
BONJESTA® should be taken on an empty stomach with a glass of water.
Severe drowsiness can occur when used in combination with alcohol or other sedating medications.
BONJESTA® is an extended-release formulation; therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion, and tachycardia. At toxic doses, doxylamine exhibits anticholinergic effects, including seizures, rhabdomyolysis, acute renal failure, and death. If treatment is needed, it consists of gastric lavage or activated charcoal, whole bowel irrigation, and symptomatic treatment. If you suspect an overdose or seek additional information about overdose treatment, call a poison control center at 1-800-222-1222.
To report suspected adverse reactions, contact Duchesnay Inc. at 1-855-722-7734 or [email protected] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
BONJESTA® is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
BONJESTA® has not been studied in women with hyperemesis gravidarum.